Abogen Biosciences' Baoshan R&D Center in Shanghai Nears Completion, Establishing an Independent Global IP Platform for mRNA Therapeutics

China Securities News (reporter Wang Lizhi) -- On November 22, the reporter learned from the "Shanghai Baoshan" WeChat Official Account that the R&D base of Abogen located in Baoshan District, Shanghai—Abogen Shanghai Center—is about to be completed. The center will focus on the fields of mRNA drugs and nanodelivery technology, building technical barriers including mRNA sequence optimization, bioinformatics analysis, in vivo and in vitro immune function evaluation, and creating an independent international intellectual property development platform for innovative mRNA drugs to promote the R&D of a series of mRNA drug products.

Abogen is one of the very few companies in the world that owns a self-developed mRNA technology platform and nanodelivery platform technology, and has obtained more than 100 international patents since its establishment.